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Abstract
Background: MUTYH-associated polyposis (MAP) is an autosomal recessive form of intestinal polyposis
predisposing to colorectal carcinoma. High resolution melting analysis (HRMA) is a mutation scanning method that
allows detection of heterozygous sequence changes with high sensitivity, whereas homozygosity for a nucleotide
change may not lead to significant curve shape or melting temperature changes compared to homozygous wild-
type samples. Therefore, HRMA has been mainly applied to the detection of mutations associated with autosomal
dominant or X-linked disorders, while applications to autosomal recessive conditions are less common.
Methods: MUTYH coding sequence and UTRs were analyzed by both HRMA and sequencing on 88 leukocyte
genomic DNA samples. Twenty-six samples were also examined by SSCP. Experiments were performed both with
and without mixing the test samples with wild-type DNA.
Results: The results show that all MUTYH sequence variations, including G > C and A > T homozygous changes,
can be reliably identified by HRMA when a condition of artificial heterozygosity is created by mixing test and
reference DNA. HRMA had a sensitivity comparable to sequencing and higher than SSCP.
Conclusions: The availability of a rapid and inexpensive method for the identification of MUTYH sequence variants
is relevant for the diagnosis of colorectal cancer susceptibility, since the MAP phenotype is highly variable.
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Background
Colorectal carcinoma (CRC) is the second most com-
mon cause of cancer-related mortality in developed
countries. About 1% of CRCs arise in individuals
affected with familial adenomatous polyposis. This con-
dition can be caused by mutations in at least 2 distinct
genes: APC, implicated in the autosomal dominant
form, and MUTYH, which is involved in MUTYH-asso-
ciated polyposis (MAP: MIM#608456). MAP is trans-
mitted as an autosomal recessive trait due to biallelic
mutations of the MUTYH gene, whose product is a
DNA glycosylase that removes adenine from A￿8-oxoG
as part of the base excision repair process [1].
MAP patients are homozygotes or compound hetero-
zygotes for mutations of the MUTYH gene, that is com-
prised of 16 exons. Two missense base substitutions,
c.536A > G (p.Tyr179Cys) and c.1187G > A (p.
Gly396Asp), located in exons 7 and 13, respectively,
account for about 75% of pathogenic MUTYH allelic
variants reported among Caucasians [2]. In addition,
other recurrent MUTYH mutations have been identified
in Pakistani, Dutch, Portuguese and Japanese patients
[3,4]. The remaining fraction of MUTYH variants identi-
fied in MAP patients is highly heterogeneous and can
be located along the whole coding sequence.
The identification of MUTYH germline mutations has
clinical relevance because the MAP phenotype is variable
and often difficult to identify on clinical grounds alone
[5-7]. The first step in MUTYH molecular screening in
Caucasian patients is usually represented by the search for
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MUTYH coding region is then carried out when none or
only one mutant allele is identified with the first screening.
Several scanning techniques are currently performed
to identify MUTYH sequence variants. These are usually
based on direct sequencing, often preceded by denatur-
ating high-performance liquid chromatography
(dHPLC), single strand conformational polymorphism
(SSCP) or Tetra-ARMS-PCR assay [8-10]. Despite their
high degree of accuracy, these methods are relatively
time-consuming and expensive.
High resolution melting analysis (HRMA) is a mutation
detection method based on the principle that the melting
curves of DNA fragments vary depending on base com-
position, and is a potentially useful technique for fast
genotyping and high-throughput mutation scanning in
genetic diagnosis [11,12]. Heterozygous samples are iden-
tified by differences in melting curve shape. When a
nucleotide change is present in a target sequence, the
resulting melting curve of the PCR product is a compo-
site of both heteroduplex and homoduplex components
that is visualized by the different melting curve shapes of
the two species present. Homozygous base changes are
not associated with heteroduplex formation. Since DNA
sequences differing in a single base often have different
melting temperatures (Tm), discrimination between
homozygous wild-type and homozygous mutant samples
can be achieved by comparing the Tm values of test sam-
ples with those of wild-type controls.
Unlike other scanning methods, mutation analysis by
HRMA provides a closed-tube system that reduces the
risk of contamination, decreases analytical time and
requires no sample processing or separation after PCR.
HRMA has been used for the detection of mutations
associated with human genetic diseases, especially auto-
somal dominant or X-linked disorders [13-15]. More
recently, this method was used to identify sequence var-
iations in autosomal recessive disorders, such as primary
carnitine deficiency, cystic fibrosis, and Zellweger syn-
drome [16-19]. This technique has also been used to
identify specific common variants in selected MUTYH
exons [20,21]. However, there is a lack of information
on the sensitivity of HRMA for the identification of a
broader spectrum of MUTYH mutations.
In this study, we report on an HRMA-based approach
for the rapid detection of MUTYH variations spread
along the entire coding region, as well as in the 5’ and
3’ untranslated regions, in both the heterozygous and
homozygous state.
Methods
DNA samples
The study was carried out on 88 genomic DNA samples
from unrelated individuals. We initially analyzed a set of
26 samples of known MUTYH genotype, previously
investigated by both SSCP analysis and direct sequencing.
These samples were obtained from healthy subjects with-
out a family history of cancer (n = 10) and from patients
with intestinal polyposis and/or early onset CRC (n =
16). The list of sequence variations identified in this con-
trol group is shown in Table 1. To validate the HRMA
method, we subsequently tested 62 samples of unknown
genotype from patients with clinical manifestations of
MAP. Patients with one of the following characteristics
were included in the initial and validation sets: 1. pre-
sence of ≥10 adenomatous or mixed adenomatous/hyper-
plastics polyps; 2. early-onset (< 40 years) sporadic CRC;
3. “multiple” polyps of unspecified number. The study
was performed in accordance to the Helsinki Declaration
(http://www.wma.net/en/30publications/10policies/b3/
index.html). Informed consent was obtained from all
patients for the use of specimens and clinical/pathologi-
cal data for research purposes according to the guidelines
established by the local ethical committee.
Genomic DNA was isolated from peripheral blood
leukocytes by phenol/chloroform extraction. DNA con-
centrations were determined by Real-Time PCR on an
ABI Prism 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA) with the Quantifiler
®
Human Quantification Kit (Applied Biosystems, Foster
City, CA).
PCR amplification
The GenBank sequence NM_001128425.1 was used as
the reference sequence for MUTYH cDNA. Primers for
exons 3, 6 and 13 and for the 3’ and 5’ UTR regions
were designed using Primer3 software (http://frodo.wi.
mit.edu/primer3/), and their sequences are available
upon request. All other exons and flanking intron
sequences were amplified using previously reported oli-
gonucleotides [22]. To increase sensitivity, we chose
amplicon sizes not greater than 300 bp and we deter-
mined the folding characteristic of both primers and
amplicons using the secondary structure profiling soft-
ware DINAMelt (http://dinamelt.bioinfo.rpi.edu/hybrid2.
php). The same primer sets were used for SSCP analysis,
HRMA, and sequencing.
For each sample, PCR for HRMA analysis was per-
formed under two different conditions: on the native
sample, and on an 85:15 mixture of the test sample and
a reference DNA sample homozygous for the wild-type
sequence. Mixtures of reference and test samples
allowed to obtain a condition of artificial heterozygosity
[23,24].
PCR reactions for HRMA were carried out in a final
volume of 15 μl containing 10-20 ng of template DNA,
0.05 U/μlo fTaq Gold Polymerase (Applied Biosystems,
F o s t e rC i t y ,C A ) ,0 . 2 5p m o l / μl each primer, 1.5 μlo f
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2.5 mM dNTPs and 0.15 μlo f5 0μM intercalating dye
Syto9
® (Invitrogen Corp., Carlsboard, CA). Cycling con-
ditions were: 10 min at 95°C, followed by 45 cycles of
30 s at 95°C, 30 s at the annealing temperature, 30 s at
72°C, and a final extension at 72°C for 20 min.
PCR experiments for SSCP and sequencing analysis
were carried out in a final volume of 20 μla n d3 0μl,
respectively, containing 100 ng of template DNA, 0.05
U/μlo fTaq Polymerase (Applied Biosystems, Foster
City, CA), 0.25 pmol/μl each primer, 1X reaction buffer,
1.5 mM MgCl2,3μl of 0.25 mM dNTPs. Cycling condi-
tions were: 10 min at 95°C, followed by 40 cycles of 30
s at 95°C, 30 s at the annealing temperature, 30 s at 72°
C, and a final extension at 72°C for 7 minutes.
HRMA
All PCR products were electrophoresed in 1.2% agarose
to verify the presence of a unique product of the
expected size before performing HRMA.
To facilitate heteroduplex formation, PCR products
not subjected to prior mixing with a wild-type sample
w e r ed e n a t u r e da t9 5 ° Cf o r1m i na n dt h e nr a p i d l y
cooled to 40°C for 1 min. Samples mixed with reference
DNA were denatured as follows: 95°C for 8 min, 75°C
for 6 min, 55°C for 6 min, 37°C for 6 min. HRMA was
Table 1 MUTYH genotypes in the 26 samples used to set up the HRMA assay
AMPLICON SSCP ANALYSIS HRMA/SEQUENCING
1 N. OF CASES
EXON 1 WT WT 26
EXON 2 WT WT 23
WT c.[64G > A]+[=] 1
c.[64G > A]+[64G > A] c.[64G > A]+[64G > A] 2
EXON 3 WT WT 26
EXON 4 WT WT 26
EXON 5 WT WT 26
EXON 6 WT WT 18
c.[504+35G > A]+[=] c.[504+35G > A]+[=] 7
c.[481G > C]+[=] c.[481G > C]+[=] 1
EXON 7 WT WT 19
c.[536A > G]+[536A > G] c.[536A > G]+[536A > G] 2
c.[536A > G]+[=] c.[536A > G]+[=] 5
EXON 8 WT WT 26
EXON 9 WT WT 26
EXON 10 WT WT 26
EXON 11 WT WT 26
EXON 12 WT WT 16
c.[1014G > C]+[=] c.[1014G > C]+[=] 6
WT c.[1014G > C]+[1014G > C] 1
c.[1147delC]+[=] c.[1147delC]+[=] 1
c.[1023_1024insGA]
2+[=] c.[1023_1024insGA]
2+[=] 1
c.[1163T > C]+[=] c.[1163T > C]+[=] 1
EXON 13 WT WT 19
c.[1187G > A]+[1187G > A] c.[1187G > A]+[1187G > A] 1
c.[1187G > A]+[=] c.[1187G > A]+[=] 4
c.[1227_1228dupGG]+[1227_1228dupGG] c.[1227_1228dupGG]+[1227_1228dupGG] 1
c.[1187-27C > T(+)1258C > A]
3 c.[1187-27C > T(+)1258C > A]
3 1
EXON 14 WT WT 24
c.[1437_1439delGGA]+[=] c.[1437_1439delGGA]+[=] 1
c.[1437_1439delGGA]+[1437_1439delGGA] c.[1437_1439delGGA]+[1437_1439delGGA] 1
EXON 15 WT WT 26
EXON 16 WT WT 26
1In bold genetic variants identified by direct sequencing and HRMA, but not by SSCP.
2Novel variant identified in this study.
3These two variants were present in the same sample, but their phase is unknown.
WT = wild-type.
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Research, Sidney, Australia). Fluorescence difference
plots were generated for each amplicon as previously
described [25]. Melting curve data for each reaction
were acquired in a wide range of temperatures (70°C to
95°C), initially at a ramping rate of 0.1°C/sec, and subse-
quently at a ramping rate of 0.05°C/sec, to allow better
resolution of heterozygous samples. Data were acquired
a n da n a l y z e du s i n gs o f t w a r ep r o v i d e dw i t ht h eR o t o r
Gene™ 6000 Instrument (Corbett Research, Sydney,
Australia). Wild-type controls were included in each
experiment.
DNA Sequencing
Direct sequencing of the PCR products was carried out
using the Big Dye Terminator Cycle Sequencing kit
(Applied Biosystems, Warrington, Cheshire, UK),
according to manufacturer’s instructions. Sequencing
r e a c t i o n sw e r ep u r i f i e du s i n gt h eD y eE x2 . 0S p i nk i t
(Qiagen, Crawley, W. Sussex, UK) and samples were run
onto an ABI 310 capillary sequencer (Applied
Biosystems).
SSCP analysis
SSCP analysis of the MUTYH coding sequence was per-
formed on genomic DNA at 10°C and 20°C on 12.5%
GeneGel Excel with a GenePhor apparatus (Amersham
Biosciences, AB, Uppsala, Sweden). Silver nitrate was
used to stain PCR products [26].
Results
As a first step, we assessed the specificity and sensitivity
of HRMA in a set of 26 samples whose genotypes had
been preliminarily determined by SSCP and direct
sequencing. All samples had been investigated by both
SSCP and sequencing in order to compare the results
obtained with the two methods. These allowed the detec-
tion of a total of 13 MUTYH point sequence variants in
the 26 samples (Table 1). All variants were identified by
SSCP, with the exception of the c.64G > A and c.1014G
> C substitutions; these were detected in the heterozy-
gous and homozygous state, respectively, only by sequen-
cing. Six variants were present in multiple samples.
In order to verify whether HRMA allowed detection of
homozygous sequence changes based on Tm differences
alone, the 26 samples were examined without prior mix-
ing with the reference sample. In all samples harbouring
MUTYH variants previously identified by SSCP, the
shapes of the melting curves were altered compared to
wild-type samples. All samples homozygous for MUTYH
sequence changes recognized by SSCP analysis (c.64G >
A, c.536A > G, c.1187G > A, c.1227_12289dupGG and
c.1437_1439delGGA) could be reproducibly distin-
g u i s h e df r o mt h ew i l d - t y p ec o u n t e r p a r t sb yat e m p e r a -
ture shift in the melting curve. In addition, HRMA
under these conditions allowed to identify one heterozy-
gote for the c.64A allele, that had gone undetected by
SSCP; this showed a melting curve clearly different from
those of wild-type c.64G homozygotes (data not shown).
We then re-examined all samples after mixing with a
reference genomic DNA. All genotypes reported in
Table 1, including the homozygote for the c.1014G > C
(p.Gln388His) variant (Figure 1), were detected by
HRMA under these conditions. Melting curves were
reproducible in duplicates of each sample and among
different samples carrying the same mutations.
Figure 1 HRMA of MUTYH exon 12. The homozygous c.1014G > C transversion is visible with HRMA only when samples are mixed with wild-
type DNA. A) HRMA of native test samples: the normalized melting curves of c.1014G > C heterozygotes are distinct from those of GG wild-type
homozygotes; the melting profiles of GG and CC homozygotes are clustered together. B) After mixing with a reference DNA, the CC sample is
clearly distinguishable from both heterozygous GC and homozygous GG samples. Homo: homozygote; het: heterozygote; WT: wild-type; deg:
degrees (°C).
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G and c.1187G > A) were clearly detected both in the het-
erozygous and homozygous state and were associated with
significant curve shape changes (Figures 2, 3). In addition
to the c.1187G > A mutation, other sequence variations in
exon 13 were recognized (Figure 2). These included one
homozygous insertion (c.1227_1228dupGG), one hetero-
zygous intronic C > T transition (c.1187-27C > T), and
one heterozygous C > A transversion (c.1258C > A). The
associated curves could be clearly distinguished from
those of wild-type and c.1187G > A samples. The c.1187-
27C > T and c.1258C > A substitutions were present in
the same sample.
Abnormal melting profiles were clearly identified also
for the remaining 5 variants. Moreover, reproducible
melting profiles were obtained for samples carrying the
polymorphic variants (c.64G > A, c.504+35G > A,
c.1014G > C) located in exons 2, 6 and 12.
The mutation detection sensitivity was 100% com-
pared to direct sequencing in samples subjected to mix-
ing with a reference DNA. Specificity was 100%, since
all abnormal profiles were associated with sequence
changes. Sensitivity of HRMA performed without mix-
ing with a reference DNA was 94% (17/18 MUTYH var-
iant genotypes recognized).
We then performed a blinded analysis by HRMA in a
set of 62 further samples of unknown genotype,
obtained from patients with clinical characteristics sug-
gestive of MAP. Again, the experiments were performed
both with and without mixing samples with the refer-
ence DNA. All samples were also investigated by direct
sequencing. We identified 15 different sequence
Figure 2 HRMA of MUTYH exon 13. All heterozygous and homozygous variants in exon 13 are clearly distinguishable from each other and
from wild-type samples without mixing with reference DNA. A) Normalized melting curves obtained for samples carrying variants c.1187G > A
(both homozygous and heterozygous), c.1187-27C > T + c.1249C > A (double heterozygous), and wild-type samples; B) Normalized melting
curves obtained for c.1187G > A (both homozygous and heterozygous) and homozygous c.1227_1228dupGG, and wild-type samples. Homo:
homozygote; het: heterozygote; WT: wild-type; deg: degrees (°C).
Figure 3 HRMA of MUTYH exon 7. Two mutations (c.536A > G and c.544C > G) were identified in this exon. A) Normalized melting curves of
c.536A > G heterozygotes and homozygotes are clearly distinct from wild-type homozygotes; on the other hand, wild-type and c.544C > G
homozygous samples have identical melting profiles; B) After mixing with a reference DNA, the c.544C > G homozygous sample is clearly
differentiated from wild-type, c.536A > G heterozygous and homozygus samples. Homo: homozygote; het: heterozygote; WT: wild-type; deg:
degrees (°C).
Tricarico et al. BMC Cancer 2011, 11:305
http://www.biomedcentral.com/1471-2407/11/305
Page 5 of 9variations in this group: 8 missense, 5 intronic and 2 in
the 5’UTR (Table 2). All variations were identified both
in mixed and unmixed samples, with the exception of
the homozygous c.1014G > C polymorphic variant and
of a base substitution in exon 7 (c.544C > G; p.Arg182-
Gly); the latter was present in a single sample, in homo-
zygosity, and could be detected only after mixing with
reference DNA (Figure 3).
Four different variants were identified in exon 2: the
intronic polymorphism c.157+30A > G, the polymorphic
missense substitution (c.64G > A; p.Val22Met), also pre-
sent in the first sample series investigated, and two addi-
tional heterozygous base substitutions leading to
aminoacid changes, c.37G > A (p.Ala13Thr) and c.56G
> A (p.Arg19Gln). The melting profiles associated with
the latter two rare variants could clearly be distin-
guished from those of samples homozygous and hetero-
zygous for p.Val22Met (Figure 4).
All samples were also subjected to sequencing, and no
further alterations were observed. Again, the sensitivity
and specificity of mutation detection by HRMA analysis
in this blinded set of samples was 100% in experiments
performed on mixtures of test and reference DNAs,
while it was lower (88%; 15/17 variant genotypes
detected) in unmixed samples.
HRMA also allowed to identify three polymorphic var-
iants in the heterozygous state, located in intron 8
(c.690+21C > A), intron 14 (c.1477-40G > C) and exon
16 (c.1544C > T; p.Ser515Phe), respectively. These were
observed both with and without mixing the samples
with the reference DNA (data not shown).
To the best of our knowledge, four of the sequence
variants identified in this study (c.-205C > A, c.37G > A,
c.544C > G, and c.1023_1024insGA) have not previously
been reported in the literature nor are they included in
the MUTYH Leiden Open Variation Database (LOVD;
http://chromium.liacs.nl/LOVD2/colon_cancer/home.
php) database.
Discussion
We have shown that MUTYH mutations can be identi-
fied with high sensitivity by HRMA both in the hetero-
zygous and in the homozygous state. HRMA sensitivity
was higher compared to SSCP and equal to direct
sequencing, the gold standard for assessing sequence
variations. We have analyzed 26 samples containing 13
DNA sequence variations located in 6 exons, using both
HRMA and SSCP. Sensitivity of HRMA analysis
appeared superior to that of SSCP, as previously
reported [27]. In particular, HRMA allowed the detec-
tion of heterozygous and homozygous sequence changes
(c.64G > A and c.1014G > C) that had not been identi-
fied by SSCP.
HRMA has been introduced very recently in molecular
genetic diagnostic laboratories and has shown several
advantages: cost-effectiveness, simplicity, absence of
Figure 4 HRMA of MUTYH exon 2. Four genotype combinations,
in addition to wild-type, are distinguishable for this exon based on
melting profile analysis, without prior mixing with a reference DNA.
Homo: homozygote; het: heterozygote; WT: wild-type; deg: degrees
(°C).
Table 2 MUTYH sequence variants identified by HRMA in
a set of 62 samples of unknown genotype
AMPLICON GENOTYPES IDENTIFIED
1 N. OF CASES
5’UTR WT 60
c.[-127C > T]+[=] 1
c.[-205C > A]+[=] 1
EXON 2 WT 54
c.[64G > A]+[=] 4
c.[64G > A]+[64G > A] 1
c.[37G > A]+[=] 1
c.[56G > A]+[=] 1
c.[157+30A > G]+[=] 1
EXON 6 WT 55
c.[504+35G > A]+[=] 7
EXON 7 WT 58
c.[536A > G]+[=] 2
c.[544C > G]+[544C > G] 1
c.[1187-27C > T]+[=] 1
EXON 8 WT 61
c.[690+21C > A]+[=] 1
EXON 12 WT 38
c.[1014G > C]+[=] 19
c.[1014G > C]+[1014G > C] 5
EXON 13 WT 7
c.[1187G > A]+[=] 1
EXON 15 WT 61
c.[1477-40G > C]+[=] 1
EXON 16 WT 58
c.[1544C > T]+[=] 4
1In bold novel variants identified in this study by HRMA. WT = wild-type.
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identify genetic variants or mutations. So far, this tech-
nique has been mainly used for the detection of muta-
tions in genes involved in X-linked and autosomal
dominant diseases, such as OTC, BRCA1, BRCA2 and
TP53 [15,28,29]. Applications to autosomal recessive
disorders have been more limited, as homozygous muta-
tions, especially G > C and A > T substitutions and
small insertions/deletions (e.g., p.Phe508del in CFTR)
may not be associated with melting curve changes and
consequently may escape detection [30]. Nevertheless,
the technique has also been successfully applied to
investigate genes associated with autosomal recessive
conditions, such as CFTR, PEX6, ABCA4, ATP7B,
C2ORF71 [18,19,31-33]. It has also been shown that the
sensitivity limits of HRMA for the detection of homozy-
gous sequence changes can be overcome by mixing the
test DNA sample with a reference wild-type DNA
[16-18,28,29,34].
López-Villar et al. [20] have recently used HRMA to
detect heterozygous and homozygous variants in
MUTYH e x o n s7 ,1 2a n d1 3i nas e r i e so f8 2p a t i e n t s
with a phenotype suggestive of MAP. The experiments
were set up without mixing samples with a reference
DNA. Hence, homozygotes for common variants in
t h e s ee x o n s ,s u c ha sc . 1 0 1 4 G>C ,a sw e l la sf o rr a r e
nucleotide changes, could have gone undetected, since
heteroduplexes could not be formed. In addition, the
melting profiles of samples heterozygous for the com-
mon c.1187G > A and for the rare c.1276C > T (p.
Arg426Cys) mutation appeared to be overlapping.
Partial MUTYH mutation screening by HRMA limited
to exons 7, 13 and 15, has been recently performed in a
series of cutaneous melanomas [21]; however, also in
this latter study, the samples had not been premixed
with reference DNA. Therefore, so far HRMA-based
approaches for the detection of MUTYH mutations have
been limited to few targeted regions of the gene. In
addition, the sensitivity of HRMA compared to that of
other mutation screening methods was not assessed in
either study.
Although the majority of MUTYH mutations present
in Caucasian MAP patients are located in exons 7 and
13, several additional pathogenic variants are scattered
over all other exons of the gene in the Caucasian popu-
lation [35]. In addition, the distribution of MUTYH
mutations differs among populations [36]. Therefore, in
order to allow maximum sensitivity, mutation scanning
needs to be performed on all MUTYH exons.
A similar situation applies to the CFTR gene, where
population-specific mutations are observed in different
populations. For this gene, it has been demonstrated
that identification of all point mutations, both at the
heterozygous and homozygous state, can be achieved by
HRMA when the whole coding sequence is investigated
[18]. In addition, it has been observed that homozygotes
for the common Caucasian p.Phe508del mutation can
only be identified when the formation of heteroduplexes
is induced by mixing with wild-type DNA [18].
We therefore developed an improved HRMA-based
MUTYH analysis protocol that scans the entire coding
region and the UTRs and increases sensitivity by mixing
the DNA test with a reference DNA. Our results con-
firm that the common Caucasian mutations in the
MUTYH gene can be reliably identified by HRMA even
when present in the homozygous state. We also found
that the Tmso fs a m p l e sh o m o z y g o u sf o re i t h e ro ft h e
two common MUTYH mutations are consistently differ-
e n tf r o mt h o s eo ft h e i rw i l d -type counterparts; this
allows simple and rapid detection of homozygotes for
these frequent variations in native test DNA samples,
without need to add reference wild-type DNA.
In addition, complete HRMA scanning of MUTYH
clearly differentiated all samples containing DNA
sequence variations, including small insertions and dele-
tions, from wild-type DNA. Importantly, samples het-
erozygous for different variants located within the same
amplicon displayed distinct melting profiles. However, it
has been pointed out that occasionally the melting
curves of samples containing two linked variants located
i nt h es a m ea m p l i c o nm a yb eu ndistinguishable from
those observed in simple heterozygotes [37]. Hence, we
advocate that the mixing strategy should be used also
for the purpose of identifying all possible heterozygote
combinations.
The availability of a rapid and inexpensive method for
the detection of MUTYH mutations is important for the
identification of individuals at increased CRC risk. Since
the phenotype associated with MUTYH mutations is
highly variable, the diagnosis of MAP is difficult on clin-
ical grounds alone [5-7,38,39]. In addition, several stu-
dies have shown that monoallelic MUTYH mutation
carriers may have a moderately increased risk of CRC
compared to the general population [40-43]. Since the
frequency of simple heterozygotes for MUTYH muta-
tions may be as high as 0.02 in Caucasian populations
[44], MUTYH testing could become a widespread
screening test to identify individuals at risk for CRC in
the general population.
Conclusions
We have set up a very fast, simple and non-expensive
mutation scanning method that identifies the most com-
mon MUTYH mutations and known polymorphic var-
iants, as well as rare DNA sequence changes spread in
the coding sequence and 5’ UTR. In Caucasian patients,
molecular screening by HRMA can be performed in two
steps: the first one to identify common variants in exons
Tricarico et al. BMC Cancer 2011, 11:305
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Page 7 of 97 and 13 without mixing with a reference DNA; the sec-
ond one should be performed using a mixture of test
and control DNA, to detect more rare changes in the
whole coding sequence when no or a single mutation
has been identified in the first stage. The implementa-
tion of a simple and sensitive method for MUTYH
mutation scanning is relevant for the diagnosis of CRC
susceptibility and for the identification of at risk indivi-
duals, who should be advised intensive surveillance.
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